Holen Sie sich die Stockscreener-App
26.57
0.34%
-0.0514
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt PFE?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$26.62
Offen:
$26.39
24-Stunden-Volumen:
7.33M
Relative Volume:
0.16
Marktkapitalisierung:
$151.00B
Einnahmen:
$62.58B
Nettoeinkommen (Verlust:
$7.79B
KGV:
19.61
EPS:
1.3551
Netto-Cashflow:
$9.08B
1W Leistung:
-2.11%
1M Leistung:
+0.15%
6M Leistung:
+6.63%
1J Leistung:
+2.27%
1-Tages-Spanne:
$26.20
$26.59
1-Wochen-Bereich:
$26.20
$27.67
52-Wochen-Spanne:
$20.91
$27.94
Pfizer Inc Stock (PFE) Company Profile
Firmenname
Pfizer Inc
Sektor
Telefon
(212) 733-2323
Adresse
66 HUDSON BOULEVARD EAST, NEW YORK, NY
Compare PFE vs LLY, JNJ, ABBV, AZN, NVS
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PFE
Pfizer Inc
|
26.56 | 151.37B | 62.58B | 7.79B | 9.08B | 1.3551 |
|
LLY
Lilly Eli Co
|
982.54 | 896.18B | 65.18B | 20.64B | 5.96B | 22.59 |
|
JNJ
Johnson Johnson
|
239.55 | 591.15B | 94.19B | 26.80B | 19.70B | 11.05 |
|
ABBV
Abbvie Inc
|
232.46 | 417.62B | 61.16B | 4.19B | 17.82B | 2.3614 |
|
AZN
Astrazeneca Plc
|
198.36 | 312.52B | 58.80B | 10.24B | 8.98B | 3.2788 |
|
NVS
Novartis Ag Adr
|
159.98 | 315.13B | 54.72B | 14.02B | 15.32B | 7.1855 |
Pfizer Inc Stock (PFE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-20 | Eingeleitet | Barclays | Underweight |
| 2026-02-12 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2026-01-07 | Fortgesetzt | UBS | Neutral |
| 2025-12-02 | Fortgesetzt | Citigroup | Neutral |
| 2025-11-13 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-04-22 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2024-12-10 | Fortgesetzt | BofA Securities | Neutral |
| 2024-11-15 | Eingeleitet | Wolfe Research | Underperform |
| 2024-10-25 | Fortgesetzt | Citigroup | Neutral |
| 2024-10-17 | Eingeleitet | Bernstein | Mkt Perform |
| 2024-08-07 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2024-03-22 | Herabstufung | Argus | Buy → Hold |
| 2024-02-23 | Eingeleitet | Guggenheim | Buy |
| 2024-01-04 | Herabstufung | TD Cowen | Outperform → Market Perform |
| 2023-10-20 | Fortgesetzt | UBS | Neutral |
| 2023-10-16 | Hochstufung | Jefferies | Hold → Buy |
| 2023-07-17 | Bestätigt | JP Morgan | Neutral |
| 2023-07-14 | Eingeleitet | HSBC Securities | Buy |
| 2023-06-29 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2023-05-11 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2023-03-06 | Eingeleitet | Jefferies | Hold |
| 2023-02-07 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2023-01-26 | Herabstufung | UBS | Buy → Neutral |
| 2023-01-17 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-01-04 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-12-13 | Hochstufung | Goldman | Neutral → Buy |
| 2022-11-18 | Eingeleitet | Credit Suisse | Outperform |
| 2022-05-23 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2022-01-05 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-01-03 | Bestätigt | Bernstein | Mkt Perform |
| 2021-12-20 | Bestätigt | Cowen | Outperform |
| 2021-12-17 | Eingeleitet | Goldman | Neutral |
| 2021-12-13 | Hochstufung | UBS | Neutral → Buy |
| 2021-12-09 | Eingeleitet | Wells Fargo | Overweight |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-07-27 | Fortgesetzt | Truist | Buy |
| 2021-05-06 | Herabstufung | Mizuho | Buy → Neutral |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Sector Perform |
| 2021-02-04 | Hochstufung | DZ Bank | Hold → Buy |
| 2020-12-16 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-11-19 | Fortgesetzt | Goldman | Neutral |
| 2020-11-10 | Fortgesetzt | Bernstein | Mkt Perform |
| 2020-10-12 | Herabstufung | Atlantic Equities | Overweight → Neutral |
| 2020-09-29 | Eingeleitet | Berenberg | Hold |
| 2020-06-16 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2020-02-27 | Eingeleitet | Barclays | Equal Weight |
| 2020-02-27 | Hochstufung | Standpoint Research | Hold → Buy |
| 2020-02-06 | Eingeleitet | Mizuho | Buy |
| 2020-01-07 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Neutral |
| 2019-07-30 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2019-07-30 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2019-06-04 | Fortgesetzt | Morgan Stanley | Overweight |
| 2019-02-20 | Fortgesetzt | Citigroup | Neutral |
| 2019-01-31 | Hochstufung | Argus | Hold → Buy |
| 2019-01-31 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2019-01-23 | Herabstufung | UBS | Buy → Neutral |
| 2018-12-11 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2018-11-01 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
Alle ansehen
Pfizer Inc Aktie (PFE) Neueste Nachrichten
Aerospace Medicine Market is Going to Boom | Major Giants Pfizer, Novartis, Bayer - openPR.com
Can Pfizer Reignite Growth Amid COVID Declines and Patent Expirations? - Zacks Investment Research
Pfizer Inc. $PFE Shares Acquired by JT Stratford LLC - MarketBeat
Picton Mahoney Asset Management Acquires Shares of 200,735 Pfizer Inc. $PFE - MarketBeat
Pfizer: Obesity Hype And Vaccine Policy Shocks (NYSE:PFE) - Seeking Alpha
Skeletal Dysplasia Market - GlobeNewswire Inc.
Cytokines Market Global Forecast 2026-2032: Precise Treatments, Strategic Partnerships, and Supply Chain Resilience Fueling the $95+ Billion Market - GlobeNewswire Inc.
Precision Trading with Pfizer Inc. (PFE) Risk Zones - Stock Traders Daily
Argus Turns Bullish on Pfizer (PFE), Highlights GLP-1 and Oncology Pipeline - Finviz
Pfizer Arbitration Gag Provision Is Lawful, Labor Board Rules - Bloomberg Law News
Pfizer’s Comirnaty update: what US patients really need now - AD HOC NEWS
Celiac Disease Market: Expanding Revenue Landscape to 2034 – DelveInsight | Zedira, Dr. Falk Pharma, Takeda, ImmunoGenX, Provention Bio, Sanofi, Topas Therapeutics GmbH, Pfizer - StreetInsider
Pfizer's Portfolio Renewal In ProgressHigh Yields For The Patient (NYSE:PFE) - Seeking Alpha
Uterine Fibroid Treatment Drugs Market Is Going to Boom Rapidly | - openPR.com
Yeast Infection Treatment Market Is Going to Boom Rapidly | Pfizer Inc., Bayer AG, GlaxoSmithKline plc, Sanofi S.A. - openPR.com
ParaZero Strengthens Global Sales Leadership with Appointment of Bat-Sheva Noy as VP - The Manila Times
Pfizer Inc. $PFE Shares Sold by Mcdonald Partners LLC - MarketBeat
Griffith & Werner Inc. Makes New Investment in Pfizer Inc. $PFE - MarketBeat
GLP-1 Receptor Agonist Business Analysis Report 2026: Market to Reach $137.4 Billion by 2030 - GlobeNewswire Inc.
Dimensional Fund Advisors LP Acquires 1,579,117 Shares of Pfizer Inc. $PFE - MarketBeat
Pfizer Inc. (NYSE:PFE) Given Average Recommendation of "Hold" by Analysts - MarketBeat
Pfizer Inc. (PFE) and Astellas Report Positive Phase 3 EV-304 Results for PADCEV Plus Keytruda in Bladder Cancer - Finviz
Pfizer (NYSE:PFE) Shares Down 2.4%Here's Why - MarketBeat
Pfizer Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Does New Oncology Data Shift The Pipeline-Driven Bull Case For Pfizer (PFE)? - simplywall.st
Pfizer CEO Has ‘A Problem With CBER Leadership’ At US FDA - Citeline News & Insights
Pfizer Advances PF-07328948 Kidney Function Study, Supporting Long-Term Pipeline Value - TipRanks
Pfizer stock: Mixed technicals and dividend focus drive a sharp downside move - Traders Union
Pfizer's Quiet Cash Comeback (NYSE:PFE) - Seeking Alpha
Victory Capital Management Inc. Increases Position in Pfizer Inc. $PFE - MarketBeat
How Innovative Diagnostics Are Supporting a Potential Approach to C. difficile - Pfizer
Could This Fuel The Next Surge in Pfizer Stock - Trefis
South Dakota Investment Council Trims Stock Position in Pfizer Inc. $PFE - MarketBeat
Pfizer-backed Priovant wins FDA priority review for lead asset - Seeking Alpha
Where Could The Next Breakout for Pfizer Stock Come From - Trefis
Pfizer CEO flags concerns with US FDA’s vaccine leadership - WTVB
Pfizer (NYSE:PFE) Trading Down 1.3%What's Next? - MarketBeat
Pfizer Adds COVID Vaccine Data On Pregnant And Immunocompromised People Showing No AE Links - Citeline News & Insights
Pfizer Inc. stock underperforms Monday when compared to competitors - MarketWatch
Argus Research Upgrades Pfizer (PFE) - Nasdaq
Pfizer (PFE) Rating Upgraded to Buy by Argus Research | PFE Stoc - GuruFocus
Pfizer at TD Cowen Conference: Strategic Growth Post-COVID - Investing.com
1 Reason I'd Happily Buy Pfizer (PFE) Stock and Never Sell - The Globe and Mail
Pfizer CEO flags issues with FDA's vaccine leadership - CNBC
A Look At Pfizer’s (PFE) Valuation After Recent Share Price Momentum And Oncology Growth Hopes - simplywall.st
Pfizer CEO flags concerns with US FDA's vaccine leadership - Reuters
Pfizer Stock: Buy, Sell or Hold After Its 11% Rally So Far in 2026? - Yahoo Finance
Pfizer withdraws Zumrad EMA filing - The Pharma Letter
Pfizer (NYSE:PFE) Upgraded by Argus to Buy Rating - MarketBeat
Pfizer (PFE) Upgraded to Buy by Argus with Positive Growth Outlo - GuruFocus
Pfizer, Inc. (PFE) Stock Analysis: Navigating the Healthcare Giant’s Growth Potential Amidst a 6.22% Dividend Yield - DirectorsTalk Interviews
Finanzdaten der Pfizer Inc-Aktie (PFE)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.36%
0.88%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):